Advertisement

Diabetes Mellitus and Renal Transplantation

  • Curtiss B. Cook
  • Harini ChakkeraEmail author
Chapter

Abstract

Diabetes mellitus remains one of the leading causes of end-stage renal disease in the USA. Among patients undergoing a renal transplant, hyperglycemia is a common occurrence. If glucose values rise to levels meeting diagnostic criteria for diabetes mellitus after transplant in persons without preexisting diabetes mellitus, the patients are said to have new-onset diabetes after transplant. This chapter reviews some of the current information regarding new-onset diabetes after transplant, concluding with a discussion about prevention strategies.

Keywords

Renal transplant Diabetes mellitus New-onset diabetes after transplant Inpatient Posttransplant diabetes mellitus 

References

  1. 1.
    National Kidney Foundation. National Kidney Foundation: Available at: https://www.kidney.org/search-results?solr-keywords=statistics&=search. Date accessed 03/24/2016. 2016; Available from.
  2. 2.
    Centers for Disease Control and Prevention. National Diabetes Statistics Report 2014. Available at: http://www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdf. Date accessed: 03/24/2016. Available from.
  3. 3.
    Baid S, Cosimi AB, Farrell ML, Schoenfeld DA, Feng S, Chung RT, et al. Posttransplant diabetes mellitus in liver transplant recipients: risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality. Transplantation. 2001;72(6):1066–72.CrossRefGoogle Scholar
  4. 4.
    Davidson J, Wilkinson A, Dantal J, Dotta F, Haller H, Hernandez D, et al. New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation. 2003;75(10 Suppl):SS3–24.PubMedGoogle Scholar
  5. 5.
    Hur KY, Kim MS, Kim YS, Kang ES, Nam JH, Kim SH, et al. Risk factors associated with the onset and progression of posttransplantation diabetes in renal allograft recipients. Diabetes Care. 2007;30(3):609–15.CrossRefGoogle Scholar
  6. 6.
    John PR, Thuluvath PJ. Outcome of patients with new-onset diabetes mellitus after liver transplantation compared with those without diabetes mellitus. Liver Transpl. 2002;8(8):708–13.CrossRefGoogle Scholar
  7. 7.
    Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant. 2003;3(2):178–85.CrossRefGoogle Scholar
  8. 8.
    Reisaeter AV, Hartmann A. Risk factors and incidence of posttransplant diabetes mellitus. Transplant Proc. 2001;33(5A Suppl):8S–18S.CrossRefGoogle Scholar
  9. 9.
    US Renal Data System. USRDS 2007 annual data report: atlas of end-stage renal disease in the United States. Bethesda: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2007.Google Scholar
  10. 10.
    Fioretto P, Steffes MW, Sutherland DE, Goetz FC, Mauer M. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med. 1998;339(2):69–75.CrossRefGoogle Scholar
  11. 11.
    Cosio FG, Kudva Y, van der Velde M, Larson TS, Textor SC, Griffin MD, et al. New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation. Kidney Int. 2005;67(6):2415–21.CrossRefGoogle Scholar
  12. 12.
    Sharif A, Baboolal K. Complications associated with new-onset diabetes after kidney transplantation. Nat Rev Nephrol. 2012;8(1):34–42.CrossRefGoogle Scholar
  13. 13.
    Meier-Kriesche HU, Arndorfer JA, Kaplan B. The impact of body mass index on renal transplant outcomes: a significant independent risk factor for graft failure and patient death. Transplantation. 2002;73(1):70–4.CrossRefGoogle Scholar
  14. 14.
    American Diabetes Association. Glycemic targets. Diabetes Care 2016;39 Suppl 1:S39–46.Google Scholar
  15. 15.
    American Association of Clinical Endocrinologists. AACE Inpatient Glycemic Control Resource Center Available at: http://resources.aace.com/. Date accessed 03/25/2016; Available from.
  16. 16.
    Moghissi ES, Korytkowski MT, DiNardo M, Einhorn D, Hellman R, Hirsch IB, et al. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Endocr Pract. 2009;15(4):353–69.CrossRefGoogle Scholar
  17. 17.
    Society of Hospital Medicine. Glycemic control resource room. Available at: http://www.hospitalmedicine.org/ResourceRoomRedesign/GlycemicControl.cfm. Date accessed: 03/25/2016; Available from.
  18. 18.
    Chakkera HA, Weil EJ, Castro J, Heilman RL, Reddy KS, Mazur MJ, et al. Hyperglycemia during the immediate period after kidney transplantation. Clin J Am Soc Nephrol. 2009;4(4):853–9.CrossRefGoogle Scholar
  19. 19.
    Healy SJ, Black D, Harris C, Lorenz A, Dungan KM. Inpatient diabetes education is associated with less frequent hospital readmission among patients with poor glycemic control. Diabetes Care. 2013;36(10):2960–7.CrossRefGoogle Scholar
  20. 20.
    Boloori A, Saghafian S, Chakkera HA, Cook CB. Characterization of remitting and relapsing hyperglycemia in post-renal-transplant recipients. PLoS One. 2015;10(11):e0142363.CrossRefGoogle Scholar
  21. 21.
    Cosio FG, Pesavento TE, Kim S, Osei K, Henry M, Ferguson RM. Patient survival after renal transplantation: IV. Impact of post-transplant diabetes. Kidney Int. 2002;62(4):1440–6.CrossRefGoogle Scholar
  22. 22.
    Woodward RS, Schnitzler MA, Baty J, Lowell JA, Lopez-Rocafort L, Haider S, et al. Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients. Am J Transplant. 2003;3(5):590–8.CrossRefGoogle Scholar
  23. 23.
    Chakkera HA, Knowler WC, Devarapalli Y, Weil EJ, Heilman RL, Dueck A, et al. Relationship between inpatient hyperglycemia and insulin treatment after kidney transplantation and future new onset diabetes mellitus. Clin J Am Soc Nephrol. 2010;5(9):1669–75.CrossRefGoogle Scholar
  24. 24.
    Wolfe RA, Ashby VB, Milford EL, Ojo AO, Ettenger RE, Agodoa LY, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med. 1999;341(23):1725–30.CrossRefGoogle Scholar
  25. 25.
    Wauters RP, Cosio FG, Suarez Fernandez ML, Kudva Y, Shah P, Torres VE. Cardiovascular consequences of new-onset hyperglycemia after kidney transplantation. Transplantation. 2012;94(4):377–82.CrossRefGoogle Scholar
  26. 26.
    Burroughs TE, Swindle J, Takemoto S, Lentine KL, Machnicki G, Irish WD, et al. Diabetic complications associated with new-onset diabetes mellitus in renal transplant recipients. Transplantation. 2007;83(8):1027–34.CrossRefGoogle Scholar
  27. 27.
    Ghisdal L, Van Laecke S, Abramowicz MJ, Vanholder R, Abramowicz D. New-onset diabetes after renal transplantation: risk assessment and management. Diabetes Care. 2012;35(1):181–8.CrossRefGoogle Scholar
  28. 28.
    Cosio FG, Pesavento TE, Osei K, Henry ML, Ferguson RM. Post-transplant diabetes mellitus: increasing incidence in renal allograft recipients transplanted in recent years. Kidney Int. 2001;59(2):732–7.CrossRefGoogle Scholar
  29. 29.
    Cruzado JM, Bestard O, Grinyo JM. Impact of extrahepatic complications (diabetes and glomerulonephritis) associated with hepatitis C virus infection after renal transplantation. Contrib Nephrol. 2012;176:108–16.CrossRefGoogle Scholar
  30. 30.
    Johnston O, Rose CL, Webster AC, Gill JS. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol. 2008;19(7):1411–8.CrossRefGoogle Scholar
  31. 31.
    Ozbay LA, Smidt K, Mortensen DM, Carstens J, Jorgensen KA, Rungby J. Cyclosporin and tacrolimus impair insulin secretion and transcriptional regulation in INS-1E beta-cells. Br J Pharmacol. 2011;162(1):136–46.CrossRefGoogle Scholar
  32. 32.
    Chakkera HA, Mandarino LJ. Calcineurin inhibition and new-onset diabetes mellitus after transplantation. Transplantation. 2013;95(5):647–52.Google Scholar
  33. 33.
    Soleimanpour SA, Crutchlow MF, Ferrari AM, Raum JC, Groff DN, Rankin MM, et al. Calcineurin signaling regulates human islet {beta}-cell survival. J Biol Chem. 2010;285(51):40050–9.CrossRefGoogle Scholar
  34. 34.
    Tsang CK, Qi H, Liu LF, Zheng XF. Targeting mammalian target of rapamycin (mTOR) for health and diseases. Drug Discov Today. 2007;12(3–4):112–24.CrossRefGoogle Scholar
  35. 35.
    Yang SB, Lee HY, Young DM, Tien AC, Rowson-Baldwin A, Shu YY, et al. Rapamycin induces glucose intolerance in mice by reducing islet mass, insulin content, and insulin sensitivity. J Mol Med (Berl). 2012;90(5):575–85.CrossRefGoogle Scholar
  36. 36.
    Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393–403.CrossRefGoogle Scholar
  37. 37.
    Lindstrom J, Ilanne-Parikka P, Peltonen M, Aunola S, Eriksson JG, Hemio K, et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet. 2006;368(9548):1673–9.CrossRefGoogle Scholar
  38. 38.
    Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia. 2006;49(2):289–97.CrossRefGoogle Scholar
  39. 39.
    Hasse J. Pretransplant obesity: a weighty issue affecting transplant candidacy and outcomes. Nutr Clin Pract. 2007;22(5):494–504.CrossRefGoogle Scholar
  40. 40.
    Cashion AK, Sanchez ZV, Cowan PA, Hathaway DK, Lo Costello A, Gaber AO. Changes in weight during the first year after kidney transplantation. Prog Transplant. 2007;17(1):40–7.CrossRefGoogle Scholar
  41. 41.
    Leavey SF, McCullough K, Hecking E, Goodkin D, Port FK, Young EW. Body mass index and mortality in ‘healthier’ as compared with ‘sicker’ haemodialysis patients: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant. 2001;16(12):2386–94.CrossRefGoogle Scholar
  42. 42.
    Salahudeen AK. Obesity and survival on dialysis. Am J Kidney Dis. 2003;41(5):925–32.CrossRefGoogle Scholar
  43. 43.
    Beddhu S, Pappas LM, Ramkumar N, Samore M. Effects of body size and body composition on survival in hemodialysis patients. J Am Soc Nephrol. 2003;14(9):2366–72.CrossRefGoogle Scholar
  44. 44.
    Kalantar-Zadeh K, Streja E, Molnar MZ, Lukowsky LR, Krishnan M, Kovesdy CP, et al. Mortality prediction by surrogates of body composition: an examination of the obesity paradox in hemodialysis patients using composite ranking score analysis. Am J Epidemiol. 2012;175(8):793–803.CrossRefGoogle Scholar
  45. 45.
    Molnar MZ, Kovesdy CP, Mucsi I, Bunnapradist S, Streja E, Krishnan M, et al. Higher recipient body mass index is associated with post-transplant delayed kidney graft function. Kidney Int. 2011;80(2):218–24.CrossRefGoogle Scholar
  46. 46.
    Weissenbacher A, Jara M, Ulmer H, Biebl M, Bosmuller C, Schneeberger S, et al. Recipient and donor body mass index as important risk factors for delayed kidney graft function. Transplantation. 2012;93(5):524–9.CrossRefGoogle Scholar
  47. 47.
    Painter P, Ward K, Nelson RD. Self-reported physical activity in patients with end stage renal disease. Nephrol Nurs J. 2011;38(2):139–47. quiz 148PubMedGoogle Scholar
  48. 48.
    Majchrzak KM, Pupim LB, Chen K, Martin CJ, Gaffney S, Greene JH, et al. Physical activity patterns in chronic hemodialysis patients: comparison of dialysis and nondialysis days. J Ren Nutr. 2005;15(2):217–24.CrossRefGoogle Scholar
  49. 49.
    Hecking M, Haidinger M, Doller D, Werzowa J, Tura A, Zhang J, et al. Early basal insulin therapy decreases new-onset diabetes after renal transplantation. J Am Soc Nephrol. 2012;23(4):739–49.CrossRefGoogle Scholar
  50. 50.
    DeFronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med. 2011;364(12):1104–15.CrossRefGoogle Scholar
  51. 51.
    Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002;359(9323):2072–7.CrossRefGoogle Scholar
  52. 52.
    Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006;368(9541):1096–105.CrossRefGoogle Scholar
  53. 53.
    Kurian B, Joshi R, Helmuth A. Effectiveness and long-term safety of thiazolidinediones and metformin in renal transplant recipients. Endocr Pract. 2008;14(8):979–84.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Division of EndocrinologyMayo Clinic College of MedicineScottsdaleUSA
  2. 2.Division of NephrologyMayo Clinic, ArizonaPhoenixUSA

Personalised recommendations